Summary Expression of Fas, an apoptosis-inducing receptor, in colonic epithelium is progressively reduced during malignant transformation. We have examined the human Fas gene for loss of heterozygosity (LOH) and gross rearrangements in colon tumours and matched normal mucosa. Polymerase chain reaction (PCR) primers were designed to span a Dral restriction fragment length polymorphic site in the gene. Heterozygosity was detected in normal DNA samples by PCR amplification of the polymorphic site and restriction enzyme digestion. Thirtyeight of 88 patients (43%) with colon carcinomas were informative for the assay, and LOH was detected in 6 of the 38 (16%) corresponding tumours. Tumours from three patients with LOH did not express detectable Fas mRNA, and Fas expression was reduced or absent in 7 of 11 tumours from informative patients without LOH. Southern blotting of tumour DNA samples was used to detect rearrangement of the Fas gene, but no altered hybridization patterns were observed in 64 tumours analysed. These findings indicate that disruption of the Fas gene is not primarily responsible for the loss of Fas protein expression reported in colon cancer. We have also shown that loss of Fas gene transcription is common in these tumours, which may be due to epigenetic gene silencing.
The size and structure of cell populations are controlled by a balance between the rates of cell renewal and death. Physiological cell death normally occurs as a series of distinct morphological and biochemical events termed apoptosis (Kerr et al, 1994) . In the colon, apoptosis contributes to the homeostasis of the epithelial layer of the mucosa, which has a rapid rate of cell turnover (Hall et al, 1994) . Apoptosis is also responsible for the removal of colonocytes with potentially oncogenic DNA damage. Recent studies on bile acids, which are genotoxic and normally induce apoptosis of colonocytes, have reported a reduction in the ability of these agents to induce apoptosis in the normal mucosa of colorectal cancer patients (Payne et al, 1995; Garewal et al, 1996) . Resistance of colonocytes to apoptosis may allow hyperproliferation, accumulation of oncogenic mutations and prevent deletion of malignant cells by chemotherapeutic agents. Abnormal expression of the apoptosis-related genes p53 and bcl-2 has been reported in both benign and malignant colon tumours (Sinicrope et al, 1995; Scott et al, 1996) , however other molecular mediators of resistance to apoptosis remain to be identified.
The Fas antigen (also called APO-1 or CD95) is a cell surface receptor, homologous to members of the tumour necrosis factor (TNF) family of transmembrane proteins (Itoh et al, 1991) . Ligation of Fas on the cell surface, by its endogenous ligand or by agonistic antibodies, triggers rapid apoptosis of the cell (Trauth et al, 1989; Yonehara et al, 1989) . Fas and Fas ligand proteins are expressed on activated T cells and Fas ligand is expressed on the surface of cytotoxic T lymphocytes (CTLs). Fas signalling is required for the apoptotic deletion of autoreactive and activated immune cells (Dhein et al, 1995) , as well as of virus-infected and malignant cells by CTLs (Rouvier et al, 1993) . Fas signalling has also been linked to apoptosis outside the lymphoid population, including the regression of ovarian follicles after ovulation and maintenance of cellular homeostasis in the liver (Adachi et al, 1995; Hakuno et al, 1996) . The epithelial layer of the normal colonic mucosa expresses Fas protein at high levels, from the bottoms of the crypts to the luminal surface (Leithauser et al, 1993; Moller et al, 1994) . A functional role for Fas receptors in the colon has not yet been demonstrated, as the Fas ligand has not been detected in the colon, except in subsets of lymphocytes in the lamina propria . Expression of Fas protein in the colon is progressively reduced during the transformation of normal epithelium to benign neoplasms, adenocarcinomas and, ultimately, to metastases (Leithauser et al, 1993; Moller et al, 1994) . Moller and co-workers (1994) reported that the extent of loss was related to the stage of the disease, as only 10% of adenomas exhibited reduced Fas expression compared with 88% of carcinomas. Total absence of Fas was most common in non-mucinous and metastatic tumours. If Fas is required for apoptosis of the colonic epithelial cells, it is possible that loss of Fas activity can contribute to the reduction in apoptotic capacity of colonic carcinomas.
In the present study, we have examined colonic tumours for gross rearrangements and deletion of the Fas gene to identify a possible mechanism by which Fas expression in the colonocytes is reduced during malignant transformation. The gene encoding the Fas protein has been mapped to human chromosome lOq23-24.1 (Inazawa et al, 1992; Lichter et al, 1992) . Loss of this chromosomal arm is relatively uncommon in colorectal cancers when detected by molecular techniques (approximately 15% ; Vogelstein et al, 1989) , however a cytogenetic analysis has reported a frequency of up to 49% (Muleris et al, 1990 (Sambrook et al, 1989) .
Detection of an RFLP in the human Fas gene A polymorphic base change (ACC to ACT) at nucleotide position 641 (relative to the translational start site) of the human Fas cDNA has been reported (Fiucci and Ruberti, 1994) . This base change creates a recognition sequence for the restriction enzyme Dral. To detect the polymorphism by polymerase chain reaction (PCR) amplification, a genomic fragment of Fas, spanning the polymorphism and a 1.1-kb intron beginning 10 bp downstream of the polymorphism, was amplified from genomic DNA using primers 1 and 2 (Table 1 ). The product was purified by spin extraction through Wizard columns (Promega, Madison, USA), cloned into a pGEM-T vector (Promega) and partly sequenced. Primer 3 was then designed from the intronic sequence (Table 1 ) and used with primer 1 to amplify a 115-bp product containing the polymorphism, which was used in the final analysis.
The 115-bp DNA sequence was amplified from genomic DNA (100 ng) by an initial denaturation of 5 min at 94°C, 35 cycles of denaturation for 1 min at 94°C, 1 min of annealing at 53°C and 1 min of elongation at 72°C; followed by a final elongation step of 5 min at 72°C. All PCR reactions contained 1 unit of Taq polymerase (Promega) in the manufacturer's buffer, 100 ng of primers 1 and 3 (Table 1) (New England BioLabs) for 3 h at 65°C. Digested samples were fractionated on 1% agarose gels and blotted onto GeneScreen Plus nylon membranes (DuPont, Boston, USA) under alkaline conditions (Koetsier et al, 1993 Northern blot analysis of Fas mRNA Frozen colon specimens, from patients who were informative for the LOH assay, were pulverized under liquid nitrogen with a mortar and pestle. The ground tissues were suspended in a lysis buffer containing 4 M guanidine thiocyanate and RNA was isolated using the phenol-chloroform-isopropanol method (Chomczynski and Sacchi, 1987) . RNA (10 jg) was electrophoresed through 1% agarose gels containing 17% formaldehyde. RNA was blotted onto GeneScreen Plus nylon membranes 
Expression of Fas mRNA in colon tumours
Fifteen informative colon tumours were analysed for Fas expression, 11 of which had matched normal mucosal RNA samples ( Figure 4 ). All except one sample of normal mucosa examined expressed the 2.7-and 1.9-kb Fas mRNA bands previously reported by Northern analysis (Itoh et al, 1991 
DISCUSSION
Apoptosis induced by the Fas antigen is vital for the programmed deletion of immune cell populations and foreign cells. Despite its widespread expression in epithelial tissues, the biological importance of Fas outside the immune system is not fully understood. Reports of abnormalities in Fas protein expression and function in colon tumours and cell lines are now prevalent in the literature and appear to be associated with a failure of apoptotic capacity of the cells. In the present study, we have verified that Fas mRNA is expressed constitutively in normal colonic mucosa, but Fas gene transcription was reduced in the majority of tumours analysed. Losses or rearrangements of chromosomes are common in tumour cells (Popescu, 1994) Fiucci and Ruberti (1994) (RieuxLaucat et al, 1995; Cascino et al, 1996; Drappa et al, 1996) (Xerri et al, 1995) . (Wu et al, 1994; Rieux-Laucat et al, 1995) , suggesting that Fas signalling can control the growth of cell populations. When lpr mice, which express little Fas protein as a result of a retroviral insertion in thefas gene, are crossed with mice that overexpress the oncogene c-myc, tumour formation occurs at a greater rate than in the c-myc-expressing mice alone (Zornig et al, 1995) . Fas deficiency also increases the incidence of B-cell lymphoma in T-cell-deficient mice to 70%, compared with 10% in T-cell-deficient mice with intact Fas protein (Peng et al, 1996) .
These findings indicate that Fas deficiency has a permissive effect on existing promalignant defects.
During the progression of colon cancer, the ability of colonic epithelial cells to undergo apoptosis in response to mutagenic challenge is compromised. The p53 protein is generally believed to be responsible for induction of apoptosis in response to DNA damage, however loss of p53 is a comparatively late event in colorectal tumorigenesis (Fearon and Vogelstein, 1990) . The molecular targets of p53 that carry out the apoptotic signal are unknown, however p53 can bind to the promoter of the Fas gene and induce its expression (Owen-Schaub et al, 1995) . If Fas is a downstream effector of p53, its loss could directly influence cell death in colonic tumours. However, the role of Fas signalling in the colon and the importance of its loss in colon cancer are still largely unknown. Fas protein is expressed in variable levels on the surface of several colon cancer cell lines. In some cell lines, low expression of Fas may be up-regulated by the cytokines TNF-a or interferon gamma (IFN-y) to levels similar to that of activated T cells (Yonehara et al, 1989; Itoh et al, 1991; Moller et al, 1994 (Yonehara et al, 1989; Abreu-Martin et al, 1995) , while growth of KM12C cells is inhibited by the anti-Fas antibody (Owen-Schaub et al, 1993 , 1994 . Metastatic variants of KM12C cells are more resistant to the effects of the antibody, despite a similar level of Fas expression (Owen-Schaub et al, 1994) . SW620 cells are resistant to Fas ligation, but also express Fas ligand at levels capable of killing T cells, thus avoiding immune deletion (O'Connell et al, 1996) . Taken together, these findings suggest that colon tumours may actively avoid immune surveillance and increase their own survival by down-regulating Fas expression or function.
The lack of detectable deletions or other rearrangements in the Fas gene in colonic tumours suggests that the gene may be transcriptionally silenced during colon cancer progression. There are recognition sequences in the Fas promoter for a number of transcriptional proteins including p53, c-myb and NF-KB (Behrmann Fas gene disruptions are rare in colonic tumours 1459 Cheng et al, 1995) ; the loss of any of which may prevent Fas expression. The promoter region of Fas is GC rich and contains a number of CpG dinucleotides. De novo methylation of CpG islands often occurs in tumours and has been associated with epigenetic silencing of tumour-suppressor genes. Future studies in this laboratory will examine the patterns of CpG methylation in the Fas gene promoter in colonic carcinomas, as a possible mechanism by which Fas gene transcription is reduced.
